{"id":78732,"date":"2024-07-09T11:58:00","date_gmt":"2024-07-09T11:58:00","guid":{"rendered":"https:\/\/www.cofb.org\/?p=78732"},"modified":"2024-07-09T12:30:53","modified_gmt":"2024-07-09T12:30:53","slug":"prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","title":{"rendered":"Cerca de 100 farmac\u00e9uticos y farmac\u00e9uticas de hospitales profundizan en los c\u00e1nceres ginecol\u00f3gicos"},"content":{"rendered":"

Los pasados meses de mayo y junio, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) <\/strong>organiz\u00f3, con la colaboraci\u00f3n de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC)<\/a> <\/strong>la formaci\u00f3n "Actualizaci\u00f3n en c\u00e1nceres ginecol\u00f3gicos"<\/strong>, con el patrocinio deAstraZeneca<\/a>. Las sesiones, dirigidas a farmac\u00e9uticos y farmac\u00e9uticas de hospital<\/strong>, fue coordinada por el vocal de Hospitales del COFB, David Conde<\/strong>, e impartida por Cristina Martin<\/strong>, onc\u00f3loga adjunta del Servicio de Oncolog\u00eda M\u00e9dica de la divisi\u00f3n de c\u00e1ncer urol\u00f3gico y ginecol\u00f3gico del Hospital de la Santa Creu i Sant Pau; \u00c1lvaro Taus<\/strong>, onc\u00f3logo adjunto del Servicio de Oncolog\u00eda M\u00e9dica de la divisi\u00f3n de c\u00e1ncer ginecol\u00f3gico y de pulm\u00f3n del Hospital del Mar; Julen Fern\u00e1ndez<\/strong>, onc\u00f3logo adjunto del Servicio de Oncolog\u00eda M\u00e9dica de la divisi\u00f3n de c\u00e1ncer ginecol\u00f3gico y gastrointestinal del Hospital Universitario M\u00fatua de Terrassa; y Milana Bergamino<\/strong>, onc\u00f3loga adjunta de la divisi\u00f3n de c\u00e1ncer de mama del Institut Catal\u00e0 d\u2019Oncologia (ICO) de Badalona.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

El objetivo de la formaci\u00f3n, que tuvo lugar los d\u00edas 30 de mayo y 6, 13 y 20 de junio, fue revisar la fisiopatolog\u00eda de los distintos c\u00e1nceres ginecol\u00f3gicos<\/strong>, actualizar la gesti\u00f3n <\/strong>y el tratamiento<\/strong> de estos c\u00e1nceres, presentar las perspectivas de futuro<\/strong> y revisar los aspectos relacionados con la atenci\u00f3n farmac\u00e9utica<\/strong> en la dispensaci\u00f3n de tratamientos para combatir este tipo de tumores.<\/strong><\/p>\n\n\n\n

La formaci\u00f3n, con cerca de 100 farmac\u00e9uticos y farmac\u00e9uticas participantes<\/strong>, compagin\u00f3 sesiones te\u00f3ricas con casos pr\u00e1cticos en los que se profundiz\u00f3 en la actualizaci\u00f3n en el tratamiento y pron\u00f3stico del c\u00e1ncer de ovario, de c\u00e9rvix, de endometrio y en c\u00e1ncer de mama<\/strong>. \u201cEsta formaci\u00f3n da respuesta a la necesidad de actualizaci\u00f3n de estos tumores<\/strong>, en relaci\u00f3n con las grandes novedades<\/strong> que han llegado en cuanto en el arsenal terap\u00e9utico para combatirlos\u201d<\/strong>, indic\u00f3 el vocal de Hospitales del COFB, David Conde<\/strong>.<\/p>\n\n\n\n

\"El<\/a>
El vocal de Hospitales del COFB, David Conde, presentando la formaci\u00f3n "Actualizaci\u00f3n en c\u00e1nceres ginecol\u00f3gicos".<\/figcaption><\/figure>\n\n\n\n

C\u00e1ncer de ovario<\/strong><\/h2>\n\n\n\n

A lo largo de la primera sesi\u00f3n, celebrada el 30 de mayo, Cristina Martin<\/strong>, onc\u00f3loga adjunta del Servicio de Oncolog\u00eda M\u00e9dica del Hospital de la Santa Creu i Sant Pau abord\u00f3 el c\u00e1ncer de ovario<\/strong>, que \u201csigue siendo el c\u00e1ncer ginecol\u00f3gico m\u00e1s letal<\/strong>\u201d. Por esta raz\u00f3n, la onc\u00f3loga apunt\u00f3 que es necesario mejorar los m\u00e9todos de cribado<\/strong> y los tratamientos de primera l\u00ednea <\/strong>para curar a los pacientes.<\/p>\n\n\n\n

\"Cristina<\/a>
Cristina Martin en un momento de su exposici\u00f3n. <\/figcaption><\/figure>\n\n\n\n

La onc\u00f3loga explic\u00f3 que, en los \u00faltimos a\u00f1os, ha habido un cambio de paradigma<\/strong> que puede ayudar a personalizar el tratamiento<\/strong>, tanto en lo que se refiere al diagn\u00f3stico como al tratamiento del c\u00e1ncer de ovario. En este sentido, expuso cu\u00e1les son las dianas terap\u00e9uticas actuales<\/strong>, sobre todo en lo que se refiere al tratamiento en primera l\u00ednea para el c\u00e1ncer de ovario avanzado. Sin embargo, hizo referencia a las novedades de los tratamientos en segunda l\u00ednea<\/strong>; en la cirug\u00eda<\/strong>, que \u201ces clave para impactar en la supervivencia\u201d; y la inmunoterapia<\/strong>, que "es el futuro"<\/strong>.<\/p>\n\n\n\n

C\u00e1ncer de c\u00e9rvix<\/strong><\/h2>\n\n\n\n

En la siguiente sesi\u00f3n, que tuvo lugar el 6 de junio, intervino el onc\u00f3logo adjunto del Servicio de Oncolog\u00eda M\u00e9dica de la divisi\u00f3n de c\u00e1ncer ginecol\u00f3gico y de pulm\u00f3n del Hospital del Mar, \u00c1lvaro Taus<\/strong>, para hablar sobre el c\u00e1ncer de c\u00e9rvix<\/strong>, \u201cla principal causa de muerte por c\u00e1ncer en \u00c1frica y en Am\u00e9rica Latina<\/strong>\u201d. El onc\u00f3logo especific\u00f3 que, en la mayor\u00eda de los casos de c\u00e1ncer de c\u00e9rvix, la causa principal <\/strong>es la infecci\u00f3n cr\u00f3nica del Virus del Papiloma Humano (VPH). <\/strong>Por ello, asegur\u00f3 que es muy importante la prevenci\u00f3n<\/strong>, mediante la vacunaci\u00f3n del VPH <\/strong>y los programas de cribado<\/strong>, para lograr el objetivo mundial<\/strong> marcado por la Organizaci\u00f3n Mundial de la Salud (OMS).<\/strong><\/p>\n\n\n\n

\"\u00c1lvaro<\/a>
\u00c1lvaro Taus durante su intervenci\u00f3n. <\/figcaption><\/figure>\n\n\n\n

A lo largo de la formaci\u00f3n sobre el c\u00e1ncer de c\u00e9rvix, \u00c1lvaro Taus, repas\u00f3 el arsenal terap\u00e9utico<\/strong> para combatir ese tipo de c\u00e1ncer. En c\u00e1nceres de c\u00e9rvix, localmente avanzados, "el tratamiento es la combinaci\u00f3n de quimioterapia", indic\u00f3. Asimismo, comparti\u00f3 que, recientemente, se ha demostrado que la combinaci\u00f3n con inmunoterapia, como el pembrolizumab en la quimioterapia, conlleva mayor supervivencia libre de progresi\u00f3n (SLP). Asimismo, el doctor detall\u00f3 los tratamientos en primera y segunda l\u00ednea y las novedades m\u00e1s recientes para combatir ese c\u00e1ncer.<\/p>\n\n\n\n

C\u00e1ncer de endometrio<\/strong><\/h2>\n\n\n\n

Por su parte, Julen Fern\u00e1ndez<\/strong>, onc\u00f3logo adjunto del Servicio de Oncolog\u00eda M\u00e9dica de la divisi\u00f3n de c\u00e1ncer ginecol\u00f3gico y gastrointestinal del Hospital Universitari M\u00fatua de Terrassa, abord\u00f3 el c\u00e1ncer de endometrio<\/strong> a lo largo de la tercera sesi\u00f3n, que tuvo lugar el pasado 13 de junio. Se trata del "tumor ginecol\u00f3gico m\u00e1s frecuente en pa\u00edses desarrollados"<\/strong>, seg\u00fan apunt\u00f3.<\/p>\n\n\n\n

\"\"<\/a>
Julen Fern\u00e1ndez en un momento de su presentaci\u00f3n. <\/figcaption><\/figure>\n\n\n\n

El onc\u00f3logo expuso elarsenal terap\u00e9utico <\/strong>para combatir ese tumor. En este sentido, explic\u00f3 que en la mayor\u00eda de los diagn\u00f3sticos en estadio I<\/strong>, la cirug\u00eda <\/strong>es la elecci\u00f3n y puede curar la enfermedad. Tambi\u00e9n hizo referencia al papel del ganglio centinela<\/strong> para priorizar o no la cirug\u00eda de ganglios y profundiz\u00f3 en el tratamiento en primera l\u00ednea<\/strong>.<\/p>\n\n\n\n

Adjuvancia en c\u00e1ncer de mama<\/strong><\/h2>\n\n\n\n

Por \u00faltimo, en la \u00faltima sesi\u00f3n formativa celebrada el 20 de junio, la onc\u00f3loga adjunta de la divisi\u00f3n de c\u00e1ncer de mama del Institut Catal\u00e0 d\u2019Oncologia (ICO) de Badalona, Milana Bergamino<\/strong>, trat\u00f3 eladyuvancia en c\u00e1ncer de mama<\/strong>. "El c\u00e1ncer de mama es la primera causa de mayor p\u00e9rdida de calidad de vida en mujeres", asegur\u00f3 Bergamino. La onc\u00f3loga hizo menci\u00f3n al hecho de que hay muchos factores de riesgo<\/strong>, aunque "se desconoce el peso espec\u00edfico de cada uno de ellos"<\/strong>.<\/p>\n\n\n\n

\"Milana<\/a>
Milana Bergamino en su intervenci\u00f3n sobre c\u00e1ncer de mama. <\/figcaption><\/figure>\n\n\n\n

A lo largo de su exposici\u00f3n, Bergamino se centr\u00f3 en el tratamiento adyuvante por el c\u00e1ncer de mama<\/strong>, que debe realizarse en tumores HER2 positivos, triples negativos y tumores de alta proliferaci\u00f3n.<\/p>\n\n\n\n

<\/div>
\n
<\/div><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n
<\/div>\n

Con la colaboraci\u00f3n de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n<\/div>\n<\/div><\/section>\n\n\n\n
<\/div>
\n
<\/div><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n
<\/div>\n

Con el patrocinio de:<\/strong><\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n<\/div>\n<\/div><\/section>","protected":false},"excerpt":{"rendered":"

Los pasados meses de mayo y junio, el Colegio de Farmac\u00e9uticos de Barcelona (COFB) organiz\u00f3, con la colaboraci\u00f3n de la Sociedad Catalana de Farmacia Cl\u00ednica (SCFC) la formaci\u00f3n "Actualizaci\u00f3n en c\u00e1nceres ginecol\u00f3gicos", con el patrocinio de 'AstraZeneca. Las sesiones, dirigidas a farmac\u00e9uticos y farmac\u00e9uticas de hospital, fue coordinada por el vocal [\u2026]<\/p>","protected":false},"author":3,"featured_media":78748,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[5062,723,5058,5055,5054,4997,753,5059,5056,5057,5050,5051,18,19,53,1038,5053,5052,68,70,5060,63,5061,484],"class_list":["post-78732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-arsenal-terapeutic","tag-cancer","tag-cancer-cervix","tag-cancer-dendometri","tag-cancer-dovari","tag-cancer-de-cervix","tag-cancer-de-mama","tag-cancer-endometri","tag-cancer-mama","tag-cancer-ovari","tag-cancers","tag-cancers-ginecologics","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmaceutics","tag-farmaceutics-hospital","tag-farmaceutiques-hospital","tag-farmaceutiques-hospitalaries","tag-farmacia","tag-formacio","tag-pronostic","tag-tractament","tag-tumors","tag-vocalia-dhospitals"],"yoast_head":"\nProp de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/es\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/es\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-09T11:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-09T12:30:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1407\" \/>\n\t<meta property=\"og:image:height\" content=\"939\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Berta Mart\u00ednez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Berta Mart\u00ednez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\"},\"author\":{\"name\":\"Berta Mart\u00ednez\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\"},\"headline\":\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics\",\"datePublished\":\"2024-07-09T11:58:00+00:00\",\"dateModified\":\"2024-07-09T12:30:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\"},\"wordCount\":1118,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"keywords\":[\"arsenal terap\u00e8utic\",\"c\u00e0ncer\",\"c\u00e0ncer c\u00e8rvix\",\"c\u00e0ncer d'endometri\",\"c\u00e0ncer d'ovari\",\"c\u00e0ncer de c\u00e8rvix\",\"c\u00e0ncer de mama\",\"c\u00e0ncer endometri\",\"c\u00e0ncer mama\",\"c\u00e0ncer ovari\",\"c\u00e0ncers\",\"c\u00e0ncers ginecol\u00f2gics\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farmac\u00e8utics\",\"farmac\u00e8utics hospital\",\"farmac\u00e8utiques hospital\",\"farmac\u00e8utiques hospital\u00e0ries\",\"Farm\u00e0cia\",\"Formaci\u00f3\",\"pron\u00f2stic\",\"tractament\",\"tumors\",\"Vocalia d'Hospitals\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\",\"url\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\",\"name\":\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"datePublished\":\"2024-07-09T11:58:00+00:00\",\"dateModified\":\"2024-07-09T12:30:53+00:00\",\"description\":\"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg\",\"width\":1407,\"height\":939},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\",\"name\":\"Berta Mart\u00ednez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"caption\":\"Berta Mart\u00ednez\"},\"url\":\"https:\/\/www.cofb.org\/es\/author\/bmartinez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/es\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","og_locale":"es_ES","og_type":"article","og_title":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.","og_url":"https:\/\/www.cofb.org\/es\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2024-07-09T11:58:00+00:00","article_modified_time":"2024-07-09T12:30:53+00:00","og_image":[{"width":1407,"height":939,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","type":"image\/jpeg"}],"author":"Berta Mart\u00ednez","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"Berta Mart\u00ednez","Tiempo de lectura":"7 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/"},"author":{"name":"Berta Mart\u00ednez","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063"},"headline":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics","datePublished":"2024-07-09T11:58:00+00:00","dateModified":"2024-07-09T12:30:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/"},"wordCount":1118,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","keywords":["arsenal terap\u00e8utic","c\u00e0ncer","c\u00e0ncer c\u00e8rvix","c\u00e0ncer d'endometri","c\u00e0ncer d'ovari","c\u00e0ncer de c\u00e8rvix","c\u00e0ncer de mama","c\u00e0ncer endometri","c\u00e0ncer mama","c\u00e0ncer ovari","c\u00e0ncers","c\u00e0ncers ginecol\u00f2gics","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farmac\u00e8utics","farmac\u00e8utics hospital","farmac\u00e8utiques hospital","farmac\u00e8utiques hospital\u00e0ries","Farm\u00e0cia","Formaci\u00f3","pron\u00f2stic","tractament","tumors","Vocalia d'Hospitals"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","url":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/","name":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d'hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","datePublished":"2024-07-09T11:58:00+00:00","dateModified":"2024-07-09T12:30:53+00:00","description":"Els passat mesos de maig i juny, el COFB va organitzar, amb la col\u00b7laboraci\u00f3 de la SCFC la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d.","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg","width":1407,"height":939},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2024\/07\/09\/prop-de-100-farmaceutics-i-farmaceutiques-dhospitals-aprofundeixen-en-els-cancers-ginecologics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Prop de 100 farmac\u00e8utics i farmac\u00e8utiques d’hospitals aprofundeixen\u00a0en els c\u00e0ncers ginecol\u00f2gics"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063","name":"Berta Mart\u00ednez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","caption":"Berta Mart\u00ednez"},"url":"https:\/\/www.cofb.org\/es\/author\/bmartinez\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg",1407,939,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-768x513.jpg",768,513,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-1024x683.jpg",1024,683,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg",1407,939,false],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0.jpg",1407,939,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2024\/07\/COFB_CANCERS-GINECOLOGICS_08072024_0-18x12.jpg",18,12,true]},"uagb_author_info":{"display_name":"Berta Mart\u00ednez","author_link":"https:\/\/www.cofb.org\/es\/author\/bmartinez\/"},"uagb_comment_info":0,"uagb_excerpt":"Els passats mesos de maig i juny, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va organitzar, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) la formaci\u00f3 \u201cActualitzaci\u00f3 en c\u00e0ncers ginecol\u00f2gics\u201d, amb el patrocini d\u2019AstraZeneca. Les sessions, adre\u00e7ades a farmac\u00e8utics i farmac\u00e8utiques d\u2019hospital, va ser coordinada pel vocal […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/78732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=78732"}],"version-history":[{"count":47,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/78732\/revisions"}],"predecessor-version":[{"id":78802,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/78732\/revisions\/78802"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media\/78748"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=78732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=78732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=78732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}